Jafron Biomedical Co Ltd

Jafron Biomedical Co Ltd maintains a strong liquidity position with a current ratio of 5.81, indicating the company can easily cover its short-term liabilities with its current assets. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.36 suggests a relatively conservative capital structure, with a moderate reliance on debt financing.

The company's profitability is robust, with a return on equity (ROE) of 15.35% and a return on assets (ROA) of 9.85%, both of which exceed the typical thresholds for strong performance in the medical equipment and supplies industry. The operating margin, calculated as operating income of 689.18 million CNY on revenue of 2.01 billion CNY, reflects a healthy margin of 34.27%. This margin is well above the industry median, indicating strong cost control and pricing power.

Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international segments. This concentration may expose the company to regulatory and economic risks specific to its home country. The company operates a single business segment, which simplifies its operations but also limits diversification.

The company's growth trajectory is positive, with a strong revenue base of 2.01 billion CNY. While no specific growth rate is provided, the company's operating cash flow of 721.22 million CNY and free cash flow of -161.98 million CNY suggest that capital expenditures are currently outpacing cash generation. The capital expenditure of 172.59 million CNY indicates ongoing investment in the business, which could support future growth.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and the diluted shares outstanding are equal to the basic shares, indicating no near-term dilution pressure. The negative net cash position is a key flag, suggesting the company may need to raise additional capital or manage its debt more effectively.

Recent investor relations data shows a strong consensus among analysts, with a mean recommendation of 1.00 (strong buy) and a mean price target of 24.23 CNY. All analysts have set the same price target, indicating a high level of agreement on the company's valuation. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.